Paeoniflorin Alleviates Lipopolysaccharide-Induced Neuroinflammation and Depression Through the Keap1/Nrf2/HO-1 Signaling Pathway
Open Access
- 13 May 2025
- journal article
- research article
- Published by MDPI AG in Antioxidants
- Vol. 14 (5) , 585
Abstract
Depression is associated with bidirectional interactions between inflammatory responses and behavioral dysfunction. Paeoniflorin (PF), a monoterpene glycoside derived from Paeonia lactiflora, exhibits potent anti-inflammatory properties. This study investigates the therapeutic effects of PF on lipopolysaccharide (LPS)-induced depression-like behaviors in mice and neuroinflammation in BV2 microglial cells. Mice were co-administered PF (20, 40, or 80 mg/kg/day) and LPS (2 mg/kg) for 7 days. Behavioral tests; Nissl staining; and Golgi, Iba1, DLG4, and cytokine assays were conducted. Additionally, hippocampal NF-κB, Nrf2, and BDNF signaling pathways were analyzed using Western blots. In BV2 cells, oxidative stress and the Nrf2/HO-1 pathway were assessed using CCK-8, flow cytometry, and Western blotting after 24 h of LPS and PF treatment. PF significantly alleviated LPS-induced depression-like behaviors, increased hippocampal neuron and dendritic spine density, and upregulated synaptic proteins (PSD95, SNAP25, and BDNF). Mechanistically, PF suppressed NLRP3 inflammasome activation via the Akt/GSK3β pathway, reduced pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), and enhanced the Nrf2/HO-1 antioxidant axis. In BV2 cells, PF restored mitochondrial membrane potential, inhibited apoptosis, and decreased cytokine levels (TNF-α, IL-1β, and IL-6) by inhibiting TLR4/NF-κB signaling. In conclusion, PF significantly improved LPS-induced depression-like behaviors and attenuated neuroinflammation in BV2 microglial cells, highlighting its potential as a therapeutic agent for inflammation-associated depression.Keywords
Funding Information
- Natural Science Foundation of Shanxi (2024JC-ZDXM-56, 2021JZ-46, 23JHQ045, 23JHQ049)
- Shanxi Fundamental Science Research Project (2024JC-ZDXM-56, 2021JZ-46, 23JHQ045, 23JHQ049)
This publication has 39 references indexed in Scilit:
- NLRP3 inflammasome in depression: A reviewInternational Immunopharmacology, 2023
- A review on the pharmacokinetics of paeoniflorin and its anti-inflammatory and immunomodulatory effectsBiomedicine & Pharmacotherapy, 2020
- Behavioral, inflammatory and neurochemical disturbances in LPS and UCMS-induced mouse models of depressionBehavioural Brain Research, 2019
- Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on NeuroinflammationMolecular Neurobiology, 2018
- Paeoniflorin attenuates depressive behaviors in systemic lupus erythematosus miceBiomedicine & Pharmacotherapy, 2018
- Paeoniflorin improves survival in LPS-challenged mice through the suppression of TNF-α and IL-1β release and augmentation of IL-10 productionInternational Immunopharmacology, 2011
- Protective Effects of Paeoniflorin Against Glutamate-Induced Neurotoxicity in PC12 Cells via Antioxidant Mechanisms and Ca2+ AntagonismCellular and Molecular Neurobiology, 2010
- A Meta-Analysis of Cytokines in Major DepressionBiological Psychiatry, 2010
- Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major DepressionBiological Psychiatry, 2009
- Cellular changes in the postmortem hippocampus in major depressionBiological Psychiatry, 2004